300 related articles for article (PubMed ID: 30236776)
21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
22. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
Randall TC; Armstrong K
Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
[TBL] [Abstract][Full Text] [Related]
23. The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial.
Gerido LH; Griggs JJ; Resnicow K; Kidwell KM; Delacroix E; Austin S; Hanson EN; Bacon E; Koeppe E; Goodall S; Demerath M; Rizzo EA; Weiner S; Hawley ST; Uhlmann WR; Roberts JS; Stoffel EM
Trials; 2023 Feb; 24(1):105. PubMed ID: 36765432
[TBL] [Abstract][Full Text] [Related]
24. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
[TBL] [Abstract][Full Text] [Related]
25. Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.
Conley CC; Rivera Rivera JN; Castro-Figueroa EM; Moreno L; Dutil J; García JD; Ricker C; Quinn GP; Soliman H; Vadaparampil ST
Transl Behav Med; 2022 Oct; 12(9):900-908. PubMed ID: 36205471
[TBL] [Abstract][Full Text] [Related]
26. Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach.
Joseph G; Kaplan C; Luce J; Lee R; Stewart S; Guerra C; Pasick R
Public Health Genomics; 2012; 15(3-4):172-80. PubMed ID: 22488460
[TBL] [Abstract][Full Text] [Related]
27. Effective Referral of Low-Income Women at Risk for Hereditary Breast and Ovarian Cancer to Genetic Counseling: A Randomized Delayed Intervention Control Trial.
Pasick RJ; Joseph G; Stewart S; Kaplan C; Lee R; Luce J; Davis S; Marquez T; Nguyen T; Guerra C
Am J Public Health; 2016 Oct; 106(10):1842-8. PubMed ID: 27552275
[TBL] [Abstract][Full Text] [Related]
28. Insights into BRCA1/2 Genetic Counseling from Ethnically Diverse Latina Breast Cancer Survivors.
Rajpal N; Muñoz J; Peshkin BN; Graves KD
J Genet Couns; 2017 Dec; 26(6):1221-1237. PubMed ID: 28374142
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
[TBL] [Abstract][Full Text] [Related]
30. A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
Hoskins KF; Tejeda S; Vijayasiri G; Chukwudozie IB; Remo MH; Shah HA; Abraham IE; Balay LE; Maga TK; Searles ER; Korah VJ; Biggers A; Stolley MR; Warnecke RB
Cancer; 2018 Sep; 124(18):3733-3741. PubMed ID: 30320429
[TBL] [Abstract][Full Text] [Related]
31. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
32. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
[No Abstract] [Full Text] [Related]
33. Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium.
Nakamura S; Kwong A; Kim SW; Iau P; Patmasiriwat P; Dofitas R; Aryandono T; Hu Z; Huang CS; Ginsburg O; Rashid MU; Sarin R; Teo SH
Public Health Genomics; 2016; 19(1):53-60. PubMed ID: 26575363
[TBL] [Abstract][Full Text] [Related]
34. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
35. Informing relatives about their hereditary or familial cancer risk: study protocol for a randomized controlled trial.
de Geus E; Aalfs CM; Verdam MG; de Haes HC; Smets EM
Trials; 2014 Mar; 15():86. PubMed ID: 24649895
[TBL] [Abstract][Full Text] [Related]
36. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Shao D; Cheng S; Guo F; Zhu C; Yuan Y; Hu K; Wang Z; Meng X; Jin X; Xiong Y; Chai X; Li H; Zhang Y; Zhang H; Liu J; Ye M
Cancer Sci; 2020 Feb; 111(2):647-657. PubMed ID: 31742824
[TBL] [Abstract][Full Text] [Related]
38. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
[TBL] [Abstract][Full Text] [Related]
39. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
[TBL] [Abstract][Full Text] [Related]
40. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
Rayes N; Bowen DJ; Coffin T; Nebgen D; Peterson C; Munsell MF; Gavin K; Lechner R; Crase J; Polinsky D; Romero I; Blank SV; Levine DA; Norquist BM; Swisher EM; Lu KH
BMC Cancer; 2019 Jul; 19(1):648. PubMed ID: 31266460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
